Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Ready to explore some of the top seasonal destinations in the country? Here are the 10 best U.S. winter getaways for a mental health refresh on a budget. Cities in Texas, Florida, and California ...

Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

Wembanyama has deep vein thrombosis in his right shoulder — a serious condition that occurs when a blood clot forms in a vein ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

GLP-1 drugs like Wegovy and Ozempic, which are made by Novo Nordisk (NVO), have seen a shortage since 2022 amid rising demand. While that shortage was in effect, it allowed compounders - drug makers ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

In an exclusive interview with the Daily Business Review, Florida attorney Sia Baker-Barnes opens up about her unexpected journey into law, the resilience that defines her career, and her mission to ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...